• Corpus ID: 76495237

HMGB1 and allergic rhinitis in children: preliminary results after corticosteroids or glycyrrhetic acid intranasal treatment

  title={HMGB1 and allergic rhinitis in children: preliminary results after corticosteroids or glycyrrhetic acid intranasal treatment},
  author={Caterina Cuppari and Annamaria Salpietro and Luisa Grasso and Sara Manti and Carmelo Salpietro},
Glycyrrhizin (GL), a major component of licorice, could be considered as a new effective drug candidate to treatment of allergy, based on its anti-inflammatory activity anti-viral effects. It has been reported that GL binds directly to high mobility group box 1 (HMGB1), and inhibits its activities. The HMGB1 is a novel pro-inflammatory cytokine that has been shown to play a role in the pathogenesis of several diseases. HMGB1 is a ubiquitous nuclear protein which, under normal conditions, is… 

HMGB1 in the Pathogenesis of Nasal Inflammatory Diseases and its Inhibition as New Therapeutic Approach: A Review from the Literature

Patients with severe symptoms have the highest serum levels and the highest extracellular expression of HMGB1, and treatment of allergic rhinitis with GA is not associated with local or systemic side effects in children and adults.

High Mobility Group Box-1 Protein and Interleukin 33 Expression in Allergic Rhinitis

The expression of HMGB1 and IL-33 were both increased in AR and may have a close relationship in AR, and both were higher in HNECs of AR.

Emerging drugs for perennial allergic rhinitis

In the last years there have been very few innovative approaches to optimize the management of AR, and some more promising advances have been shown for allergen immunotherapy, where a number of new strategies are currently under development.

Nasal High-Mobility Group Box-1 Protein in Children with Allergic Rhinitis

Nasal HMGB1 levels in nasal lavage fluid were significantly increased in children with AR and is significantly related to symptom severity, which is more evident in the severe subgroup.

Allergic rhinitis: current options and future perspectives

Available and new drugs under investigation seem able to control rhinitis symptoms without a significant patient's burden, and the challenge for the next years will be to improve treatment adherence rather than to introduce new drugs.

Current recommendations and emerging options for the treatment of allergic rhinitis

An update on AR treatment is provided, with a focus on current therapies defined by AR and its impact on asthma guidelines and with a particular emphasis on new and future therapeutic perspectives.

HMGB1: A multifunctional alarmin driving autoimmune and inflammatory disease

Findings indicate that HMGB1 might be an important mediator and biomarker in rheumatic diseases as well as a target of new therapy.

Introduction: HMGB1 in inflammation and innate immunity

The high-mobility group box-1 (HMGB1), also termed HMG1andamphoterin, is themostabundant member of the HMG family of DNA-binding proteins and is released to the extracellular space upon cell damage and also as a result of active secretion.

HMGB1 and Cord Blood: Its Role as Immuno-Adjuvant Factor in Innate Immunity

The increased HMGB1 expression/secretion triggered by ABs, previously characterized for their immuno-modulating and immune-adjuvant capabilities, indicated that immunomodulation might represent a new therapeutical approach for neonatal and adult pathologies.

Mini‐review: The nuclear protein HMGB1 as a proinflammatory mediator

Therapeutic administration of HMGB1 antagonists rescues mice from lethal sepsis, even when initial treatment is delayed for 24 h after the onset of infection, establishing a clinically relevant therapeutic window that is significantly wider than for other known cytokines.

Glycyrrhizin alleviates experimental allergic asthma in mice.

Glycyrrhizin Inhibits Interleukin-8 Production and Nuclear Factor–κ B Activity in Lung Epithelial Cells, but Not Through Glucocorticoid Receptors

Findings indicated that GL had a glucocorticoid-like inhibitory effect on IL-8 production via a mechanism that differs from that of glucoc Corticoids.

The nuclear protein HMGB1 is secreted by monocytes via a non‐classical, vesicle‐mediated secretory pathway

It is shown that activation of monocytes results in the redistribution of HMGB1 from the nucleus to cytoplasmic organelles, which display ultrastructural features of endolysosomes, which means that in monocytes, non‐classical secretion can occur through vescicle compartments that are at least partially distinct.

Cell migration: HMGB1-mediated inflammatory cell recruitment

    O. Leavy
    Biology, Medicine
    Nature Reviews Immunology
  • 2012
It is shown that, in addition to causing DC depletion, DT administration unexpectedly results in an early increase (within 24 hours) in blood neutrophils in Cd11c.DTR mice, a transgenic mouse model in which DCs are conditionally depleted by injection of diphtheria toxin.

Release of chromatin protein HMGB1 by necrotic cells triggers inflammation

This corrects the article to show that the method used to derive the H2O2 “spatially aggregating force” is based on a two-step process, not a single step, like in the previous version of this paper.